White Paper - Why Diagnostic Regulation Matters in Pharmaceutical Development - and Current Best Practices
Born out of a World CDx Summit, Hanson Wade has partnered with key opinion leaders from Johnson & Johnson, Bristol Myers Squibb, Eli Lilly, Merck, Sanofi, Daiichi Sankyo, Regeneron, and others to provide a critical pharma perspective on the evolving regulatory landscape for biomarkers and companion diagnostics.
Download the white paper to gain:
- Key insights into the role of diagnostics in pharmaceutical development and regulatory expectations
- A high-level overview of regulatory environments in the US, EU, Japan, and China
- Best practices for aligning diagnostic and therapeutic development to drive innovation and improve patient access to precision therapies
What’s more, a handful of the leading authors will be joining a panel at the 15th World Clinical Biomarkers & CDx Summit to take an in-depth discussion on some key challenges discussed in this white paper – see the full panel synopsis here.
Explore the New Agenda
Hear the latest imaging, multi-omics, single-cell and functional assays, enhanced by AI-driven digital biomarker strategies, enabling earlier and smarter treatment decisions for oncology, autoimmune, neurological, chronic and rare disease patients
Prioritize Partnering with Us
Take up a partnering slot to stand alongside leading biomarker, diagnostic and technology providers, ensure your brand is front and center, and retain your position as the partner of choice in the ever-expanding precision medicine space
Join 850+ Specialist Experts
Be part of the liveliest Rx-Dx conversations with like-minded industry peers spanning a range of precision therapy modalities, and build high-value connections during dedicated networking sessions designed to foster collaborations